Our Blog

Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers
08/01/2024

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today secured an…

Read More
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers
21/09/2023

September 21, 2023 Debiopharm to boost its ADC oncology pipeline through multi-asset partnership with SunRock’s antibody portfolio integrating Multilink™ & AbYlink™…

Read More
Research activity starts in Santiago at the Sionlla Biopolo with the installation of SunRock and Zinpro
08/05/2023

The company from Santiago de Compostela is searching for antibodies against cancer, while the multinational is working on animal welfare. The…

Read More
SunRock Biopharma and VHIO are beneficiaries of a project funded with 1.7 million euros for the development of new antibodies for the treatment of solid tumors
24/03/2023

The initiative aims to advance the development of new therapeutic options for breast cancer, colorectal cancer, and head and neck cancer….

Read More
SunRock Biopharma and IDIS secure 1.8 million euros in funding for the IMPANC project.
27/02/2023

This initiative aims to advance the study of a new and effective therapeutic alternative that improves the lives of pancreatic cancer…

Read More
SunRock Biopharma receives the Bioga Award as a Competitive BioCompany
20/01/2023

The company’s experience and trajectory in the development of cancer treatments have made SunRock worthy of this recognition. The Business Technology…

Read More
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein
21/09/2022

Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours   LONDON and SANTIAGO DE COMPOSTELA, Spain,…

Read More
Axencia Galega de Innovación